Immuron Ltd - ESG Rating & Company Profile powered by AI
The report of Immuron Ltd uses data points from across the internet as well as from public filings by Immuron Ltd. This Sustainability rating for Immuron Ltd indicates the company's transparency towards the UN SDGs. Scroll down to the bottom of the page for potential risks for Immuron Ltd based on sector, location and marketcap.
Immuron Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.8; made up of an environmental score of 4.0, social score of 5.3 and governance score of 8.0.
5.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 521 | Smruthi Organics Ltd | 5.9 | High |
| 521 | Vectura Group PLC | 5.9 | High |
| 541 | Immuron Ltd | 5.8 | High |
| 541 | Cantargia AB | 5.8 | High |
| 541 | Amplia Therapeutics Ltd | 5.8 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Immuron Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Immuron Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Immuron Ltd report the average age of the workforce?
Sign up for free to unlockDoes Immuron Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Immuron Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Immuron Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Immuron Ltd offer flexible work?
Sign up for free to unlockDoes Immuron Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Immuron Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Immuron Ltd conduct supply chain audits?
Sign up for free to unlockDoes Immuron Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Immuron Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Immuron Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Immuron Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Immuron Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Immuron Ltd disclose water use targets?
Sign up for free to unlockDoes Immuron Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Immuron Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Immuron Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Immuron Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Immuron Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Immuron Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Immuron Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Immuron Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Immuron Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Immuron Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Immuron Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Immuron Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Immuron Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Immuron Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Immuron Ltd disclose its waste policy?
Sign up for free to unlockDoes Immuron Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Immuron Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Immuron Ltd disclose energy use targets?
Sign up for free to unlockDoes Immuron Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Immuron Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Immuron Ltd
These potential risks are based on the size, segment and geographies of the company.
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.